INTRODUCTION AND OBJECTIVES: Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are reported to predict clinical outcomes in patients with metastatic renal cell carcinoma (mRCC). Adjuvant sunitinib (SU) significantly improved disease-free survival (DFS) vs placebo (PBO) in patients with locoregional RCC at high risk of recurrence post nephrectomy (S-TRAC trial) . This study aimed to evaluate NLR and PLR as potential prognostic factors in high-risk loco-regional non-metastatic RCC.
METHODS: Post-hoc exploratory analysis of the high-risk S-TRAC trial patients. Kaplan-Meier estimates and Cox proportional analyses were performed on baseline and change from baseline at Week 4 NLR and PLR to assess their association with DFS. P-values were two-sided and based on an unstratified log-rank test.
RESULTS: 609/615 patients had NLR and PLR baseline values; 574 patients had paired values at both baseline and at Week 4. Cut-off values were defined as NLR <3 vs !3 and PLR <140 vs !140, based on ROC curves. The significantly shorter DFS of baseline NLR <3 vs NLR !3 in PBO patients (HR 0.63, P[0.04) CONCLUSIONS: Low baseline NLR, and a !25% decrease in NLR or PLR after 4 weeks, could both be early predictors of those highrisk patients most likely to benefit from adjuvant SU. NLR and PLR changes at Week 4 appeared to separate those most likely to tolerate and respond to adjuvant SU, eliminating potential toxicity risk in those least likely to benefit. Source of Funding: Pfizer Inc.
MP25-18 PURE TRANSABDOMINAL APPROACH FOR RENAL CELL CARCINOMA WITH SUPRADIAPHRAGMATIC TUMOR THROMBUS: A SINGLE-INSTITUTION INITIAL EXPERIENCE IN CHINA
Hai Bi*, Guoliang Wang, Yi Huang, Lulin Ma, Beijing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Curative surgery is the only reasonable chance for the cure of renal cell carcinoma with supradiaphragmatic tumor thrombus. However, sternotomy, cardiopulmonary bypass (CBP) as well as deep hypothermic circulatory arrest (DHCA) significantly increased the chances of perioperative morbidity and mortality. Here, we described our modified surgical technique to remove the supradiapharagmatic tumor thrombus through an abdominal incision without sternotomy, CBP and DHCA, and investigated the safety and effective of this technique.
METHODS: Between April 2015 and January 2018, we enrolled eight patients from our hospital, who underwent radical nephrectomy with removal of a level IV tumor thrombus through an abdominal incision using a transdiaphragmatic approach. Sternotomy, CBP and DHCA were not used. All clinical information, including patient demographics, operative variables and postoperative outcomes were retrospectively reviewed and analyzed.
RESULTS: All patients were operated successfully without the use of sternotomy, CBP and DHCA. The median operative time was 7 hours 23.2 minutes. Median estimated blood loss was 2950mL. All patients received blood transfusion with median blood infusion of 2150mL. Two patients with Buddi-Chiari syndrome preoperative developed postoperative hydrothorax resulting from pleuro-abdominal fistula. All patients were alive at the last follow-up during a follow-up of 3.5 to 36 months. One patient experienced metastatic progression disease 1 year after surgery.
CONCLUSIONS: Our experience revealed that this technique was effective and safety in selected patients with supradiaphragmatic tumor thrombus. However, patients with a large amount of ascitic fluid resulting from Buddi-Chiari syndrome should be alert to develop hydrothorax postoperatively resulting from pleuro-abdominal fistula.
Source of Funding: none

MP25-19 IMPACT OF DISAGREEMENT BETWEEN TWO RISK GROUP MODELS ON PROGNOSIS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Kazutaka Okita*, Shingo Hatakeyama, Hirosaki, Japan; Toshikaki Tanaka, Sapporo, Japan; Yoshinori Ikehata, Toyama, Japan; Toshikazu Tanaka, Aomori, Japan; Naoki Fujita, Hirosaki, Japan; Yusuke Ishibashi, Aomori, Japan; Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Hirosaki, Japan; Kazuaki Yoshikawa, Mutsu, Japan; Toshiaki Kawaguchi, Aomori, Japan; Naoya Masumori, Sapporo, Japan; Hiroshi Kitamura, Toyama, Japan; Chikara Ohyama, Hirosaki, Japan INTRODUCTION AND OBJECTIVES: To investigate the impact of the risk group disagreement between the Memorial Sloan Kettering Cancer Center (MSKCC) and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) models on prognosis, as the clinical implication of the risk group disagreement between the risk models remains unclear.
METHODS: We retrospectively evaluated 176 patients with metastatic renal cell carcinoma (mRCC) who were treated with tyrosine
